Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease.

Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RC, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF.

Neurology. 1996 Sep;47(3):705-11.

PMID:
8797468
2.

A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.

Thal LJ, Calvani M, Amato A, Carta A.

Neurology. 2000 Sep 26;55(6):805-10.

PMID:
10994000
3.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
4.

Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia.

Rai G, Wright G, Scott L, Beston B, Rest J, Exton-Smith AN.

Curr Med Res Opin. 1990;11(10):638-47.

PMID:
2178869
5.

Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.

Aronson S, Van Baelen B, Kavanagh S, Schwalen S.

Drugs Aging. 2009;26(3):231-9. doi: 10.2165/00002512-200926030-00004.

PMID:
19358618
6.

Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease.

Pettegrew JW, Klunk WE, Panchalingam K, Kanfer JN, McClure RJ.

Neurobiol Aging. 1995 Jan-Feb;16(1):1-4.

PMID:
7723928
9.

Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.

Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund LO, Palmblad J.

Arch Neurol. 2006 Oct;63(10):1402-8.

PMID:
17030655
10.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
11.

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease.

Bae CY, Cho CY, Cho K, Hoon Oh B, Choi KG, Lee HS, Jung SP, Kim DH, Lee S, Choi GD, Cho H, Lee H.

J Am Geriatr Soc. 2000 Dec;48(12):1566-71.

PMID:
11129744
12.

Long-term acetyl-L-carnitine treatment in Alzheimer's disease.

Spagnoli A, Lucca U, Menasce G, Bandera L, Cizza G, Forloni G, Tettamanti M, Frattura L, Tiraboschi P, Comelli M, et al.

Neurology. 1991 Nov;41(11):1726-32.

PMID:
1944900
13.
15.

Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.

Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M.

J Clin Pharm Ther. 2003 Feb;28(1):53-9.

PMID:
12605619
16.

Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.

Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG.

Neurology. 2003 Dec 9;61(11):1498-502.

PMID:
14663031
18.

The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.

Katz I, de Deyn PP, Mintzer J, Greenspan A, Zhu Y, Brodaty H.

Int J Geriatr Psychiatry. 2007 May;22(5):475-84.

PMID:
17471598
19.
20.

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.

Morris JC, Cyrus PA, Orazem J, Mas J, Bieber F, Ruzicka BB, Gulanski B.

Neurology. 1998 May;50(5):1222-30.

PMID:
9595967
Items per page

Supplemental Content

Write to the Help Desk